دورية أكاديمية
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
| العنوان: | Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia |
|---|---|
| المؤلفون: | Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano, Carlos, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime |
| المساهمون: | Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Lui, Sanz, Miguel Ángel, Solano, Carlo, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Cyclophosphamide, Humans, Mycophenolic Acid, Retrospective Studies, Sirolimus, Transplantation Conditioning, Unrelated Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute |
| الوصف: | Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35680995; info:eu-repo/semantics/altIdentifier/wos/WOS:000808391500001; volume:57; issue:9; firstpage:1389; lastpage:1398; numberofpages:10; journal:BONE MARROW TRANSPLANTATION; http://hdl.handle.net/20.500.11768/132811Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131605087 |
| DOI: | 10.1038/s41409-022-01725-3 |
| الإتاحة: | https://doi.org/20.500.11768/132811Test https://doi.org/10.1038/s41409-022-01725-3Test https://hdl.handle.net/20.500.11768/132811Test |
| رقم الانضمام: | edsbas.B60CFE05 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41409-022-01725-3 |
|---|